Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| KL0810CH | Other Identifier | company internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
| ||
| Group 2 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telmisartan (Kinzal/Pritor, BAY68-9291) | Drug | Patients under daily life treatment receiving Kinzal according to local drug information. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Blood pressure | After 1-2 weeks, 1month, 3-4 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Mean heart rate (bpm) | Baseline and 3-4 month | |
| Change in Mean Weight (kg) | Baseline and 3-4 month | |
| Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Community
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Switzerland |
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077333 | Telmisartan |
| D006852 | Hydrochlorothiazide |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
| Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide | Drug | Patients under daily life treatment receiving Kinzalplus according to local drug information. |
|
| Baseline and 3-4 month |
| Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatment | Baseline |
| Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician. | After 3-4 month |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D002740 | Chlorothiazide |
| D001581 | Benzothiadiazines |
| D013449 | Sulfonamides |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D049971 | Thiazides |